Related Experiment Videos
Gamma-interferon in myelodysplastic syndromes: a pilot study
I Schwarzinger1, C Stain, P Bettelheim
1First Department of Medicine, University of Vienna, Austria.
Oncology
|January 1, 1990
Summary
Recombinant gamma-interferon showed minimal benefit for myelodysplastic syndromes (MDS). The treatment did not induce remission and carried a risk of developing acute leukemia in some patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Current treatments for MDS aim to improve blood counts and reduce the risk of transformation to acute myeloid leukemia.
- Recombinant gamma-interferon (IFN) has been explored as a potential therapeutic agent for MDS.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant gamma-interferon in patients with myelodysplastic syndromes.
- To assess the potential of gamma-IFN to induce remission or improve hematological parameters in MDS patients.
Main Methods:
- Eight patients with myelodysplastic syndromes (MDS) received three cycles of recombinant gamma-interferon.
- Treatment involved subcutaneous injections at a daily dose of 0.1 mg/m2 over 14-day periods, with 2-week intervals between cycles.
Main Results:
- No complete or partial remission was observed in any patient.
- One patient showed a significant hemoglobin increase (7 to >12 g/dl).
- Two patients experienced minor improvements in platelet counts; however, three patients progressed to acute leukemia during treatment.
Conclusions:
- Recombinant gamma-interferon, administered as per this trial's schedule, demonstrated minimal beneficial effects in MDS patients.
- The observed risk of acute leukemia transformation warrants caution when considering gamma-IFN for MDS treatment.